Literature DB >> 34643757

[62/m-acute lumbago and prostate-specific antigen 1430 ng/ml : Preparation for the medical specialist examination: part 22].

Miriam Hegemann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34643757     DOI： 10.1007/s00120-021-01664-9

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  5 in total

1.  Adverse events associated with hormonal therapy for prostate cancer.

Authors:  Ravi J Kumar; Al Barqawi; E David Crawford
Journal:  Rev Urol       Date:  2005

Review 2.  Androgen deprivation therapy: indications, methods of utilization, side effects and their management.

Authors:  Diana E Magee; Rajiv K Singal
Journal:  Can J Urol       Date:  2020-02       Impact factor: 1.344

3.  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Giri Sulur; Yesenia Luna; Susan Li; Suneel Mundle; Kim N Chi
Journal:  Lancet Oncol       Date:  2019-04-12       Impact factor: 41.316

Review 4.  Adverse effects of androgen deprivation therapy and strategies to mitigate them.

Authors:  Paul L Nguyen; Shabbir M H Alibhai; Shehzad Basaria; Anthony V D'Amico; Philip W Kantoff; Nancy L Keating; David F Penson; Derek J Rosario; Bertrand Tombal; Matthew R Smith
Journal:  Eur Urol       Date:  2014-08-02       Impact factor: 20.096

5.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Christopher J Sweeney; Yu-Hui Chen; Michael Carducci; Glenn Liu; David F Jarrard; Mario Eisenberger; Yu-Ning Wong; Noah Hahn; Manish Kohli; Matthew M Cooney; Robert Dreicer; Nicholas J Vogelzang; Joel Picus; Daniel Shevrin; Maha Hussain; Jorge A Garcia; Robert S DiPaola
Journal:  N Engl J Med       Date:  2015-08-05       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.